Profile data is unavailable for this security.
About the company
Summit Therapeutics Inc. is a biopharmaceutical company focused on the discovery, development, and commercialization of patient, physician and caregiver medicinal therapies. The Company's development candidate is ivonescimab, a potential first-in-class bispecific antibody intending to combine the effects of immunotherapy via a blockade of PD-1 with the anti-angiogenesis effects of an anti-VEGF compound into a single molecule. It develops ivonescimab in non-small cell lung cancer (NSCLC), specifically launching Phase III clinical trials in the indications such as ivonescimab combined with chemotherapy in patients with epidermal growth factor receptor (EGFR)-mutated, locally advanced or metastatic non-squamous NSCLC who have progressed after treatment with a third-generation EGFR tyrosine kinase inhibitor (HARMONi), and ivonescimab combined with chemotherapy in first-line metastatic squamous NSCLC patients (HARMONi-3). Its ivonescimab is engineered with Akeso's Tetrabody technology.
- Revenue in USD (TTM)0.00
- Net income in USD-116.03m
- Incorporated2020
- Employees105.00
- LocationSummit Therapeutics Inc2882 Sand Hill Road, Suite 106MENLO PARK 94025United StatesUSA
- Phone+1 (650) 460-8308
- Fax+1 (302) 655-5049
- Websitehttps://www.smmttx.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Krystal Biotech Inc | 95.95m | 57.16m | 5.08bn | 229.00 | 94.46 | 6.35 | 80.05 | 52.91 | 1.88 | 1.88 | 3.38 | 28.02 | 0.1385 | -- | -- | 418,991.30 | 8.25 | -11.50 | 8.78 | -12.01 | 94.25 | -- | 59.57 | -492.85 | 12.42 | -- | 0.00 | -- | -- | -- | 107.81 | -- | 39.49 | -- |
| Apellis Pharmaceuticals Inc | 524.07m | -417.27m | 5.10bn | 702.00 | -- | 19.10 | -- | 9.73 | -3.46 | -3.46 | 4.33 | 2.20 | 0.5788 | 0.5747 | 3.50 | 746,538.40 | -46.09 | -73.88 | -57.28 | -90.03 | 86.47 | -- | -79.62 | -326.49 | 3.02 | -39.71 | 0.6087 | -- | 425.83 | -- | 18.94 | -- | -- | -- |
| Hims & Hers Health Inc | 959.40m | -2.35m | 5.10bn | 1.05k | -- | 14.78 | 633.84 | 5.32 | -0.0145 | -0.0145 | 4.46 | 1.61 | 2.33 | 6.68 | 176.36 | 917,209.40 | -0.5704 | -- | -0.6968 | -- | 82.41 | -- | -0.245 | -- | 2.48 | -- | 0.00 | -- | 65.49 | -- | 64.15 | -- | -- | -- |
| BridgeBio Pharma Inc | 218.60m | -538.26m | 5.21bn | 550.00 | -- | -- | -- | 23.85 | -3.23 | -3.23 | 1.29 | -5.61 | 0.2964 | -- | -- | 397,449.10 | -74.13 | -72.44 | -90.19 | -89.72 | 98.91 | 94.41 | -250.09 | -1,225.66 | -- | -11.48 | 2.53 | -- | -88.02 | -- | -33.67 | -- | -40.94 | -- |
| Organon & Co | 6.35bn | 1.05bn | 5.25bn | 10.00k | 5.00 | 108.74 | 4.06 | 0.8266 | 4.08 | 4.08 | 24.71 | 0.1876 | 0.5603 | 2.18 | 4.24 | 634,700.00 | 9.24 | 16.53 | 11.79 | 20.97 | 59.04 | 65.12 | 16.50 | 26.79 | 1.15 | 2.36 | 0.9945 | 8.25 | 1.44 | -8.52 | 11.56 | -13.83 | 20.72 | -- |
| Viking Therapeutics Inc | 0.00 | -93.72m | 5.74bn | 28.00 | -- | 6.14 | -- | -- | -0.9305 | -0.9305 | 0.00 | 8.47 | 0.00 | -- | -- | 0.00 | -16.76 | -21.91 | -17.52 | -23.04 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -24.73 | -- | -- | -- |
| Summit Therapeutics Inc | 0.00 | -116.03m | 5.89bn | 105.00 | -- | 133.22 | -- | -- | -0.1657 | -0.1657 | 0.00 | 0.063 | 0.00 | -- | -- | 0.00 | -53.76 | -77.32 | -59.38 | -86.35 | -- | -- | -- | -20,989.46 | -- | -118.81 | 0.6934 | -- | -100.00 | -- | -680.54 | -- | -4.84 | -- |
| Madrigal Pharmaceuticals Inc | 0.00 | -444.28m | 5.92bn | 376.00 | -- | 6.75 | -- | -- | -23.08 | -23.08 | 0.00 | 41.13 | 0.00 | -- | -- | 0.00 | -62.81 | -62.09 | -73.92 | -74.81 | -- | -- | -- | -- | 9.39 | -- | 0.1201 | -- | -- | -- | -26.50 | -- | 132.01 | -- |
| Ionis Pharmaceuticals Inc | 776.62m | -384.77m | 5.93bn | 927.00 | -- | 19.99 | -- | 7.64 | -2.67 | -2.67 | 5.40 | 2.03 | 0.275 | 0.379 | 81.52 | 837,777.80 | -13.62 | -6.30 | -15.20 | -7.44 | 98.72 | 98.75 | -49.54 | -21.23 | 7.28 | -- | 0.8114 | -- | 34.10 | 5.60 | -35.80 | -- | 11.83 | -- |
| Cytokinetics, Inc. | 3.75m | -530.60m | 6.26bn | 423.00 | -- | -- | -- | 1,668.04 | -5.40 | -5.40 | 0.0382 | -3.78 | 0.0044 | -- | 4.08 | 8,869.98 | -62.50 | -43.14 | -69.19 | -47.22 | -- | -- | -14,141.74 | -540.47 | -- | -15.26 | 2.78 | -- | -92.04 | -24.89 | -35.30 | -- | 9.76 | -- |
| Halozyme Therapeutics, Inc. | 862.99m | 318.80m | 6.30bn | 373.00 | 20.48 | 35.41 | 15.71 | 7.30 | 2.42 | 2.42 | 6.54 | 1.40 | 0.4874 | 1.34 | 4.42 | 2,313,644.00 | 18.01 | 18.22 | 19.22 | 21.97 | 78.50 | 79.05 | 36.94 | 39.36 | 5.36 | 966.62 | 0.8941 | 0.00 | 25.62 | 40.43 | 39.31 | -- | 26.82 | -- |
| Exelixis Inc | 1.85bn | 205.05m | 6.33bn | 1.31k | 33.62 | 3.01 | 27.50 | 3.43 | 0.6466 | 0.6466 | 5.84 | 7.21 | 0.621 | 3.12 | 7.78 | 1,409,653.00 | 6.90 | 8.86 | 7.82 | 9.91 | 95.70 | 96.30 | 11.10 | 15.43 | 3.41 | -- | 0.00 | 0.00 | 13.60 | 16.47 | 13.98 | -21.34 | 3.98 | -- |
| Revolution Medicines Inc | 4.57m | -484.27m | 6.37bn | 411.00 | -- | 3.69 | -- | 1,395.48 | -3.76 | -3.76 | 0.035 | 10.46 | 0.0031 | -- | 2.29 | 12,079.37 | -32.48 | -29.76 | -34.18 | -32.59 | -- | -- | -10,606.04 | -606.93 | -- | -- | 0.00 | -- | -67.27 | -10.50 | -75.46 | -- | 38.82 | -- |
| Blueprint Medicines Corp | 282.21m | -288.29m | 6.61bn | 645.00 | -- | 21.27 | -- | 23.42 | -4.82 | -4.82 | 4.59 | 4.96 | 0.2499 | 0.3531 | 6.18 | 430,853.40 | -25.53 | -29.92 | -30.68 | -34.06 | 96.97 | -- | -102.15 | -116.65 | 3.61 | -23.37 | 0.4352 | -- | 22.22 | 41.14 | 9.06 | -- | 4.85 | -- |
Data as of Jun 14 2024. Currency figures normalised to Summit Therapeutics Inc's reporting currency: US Dollar USD
5.52%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| BlackRock Fund Advisorsas of 31 Mar 2024 | 8.66m | 1.23% |
| SSgA Funds Management, Inc.as of 31 Mar 2024 | 8.11m | 1.16% |
| Fidelity Management & Research Co. LLCas of 31 Mar 2024 | 7.97m | 1.14% |
| The Vanguard Group, Inc.as of 31 Mar 2024 | 6.92m | 0.99% |
| Geode Capital Management LLCas of 31 Mar 2024 | 3.15m | 0.45% |
| Northern Trust Investments, Inc.(Investment Management)as of 31 Mar 2024 | 1.07m | 0.15% |
| Charles Schwab Investment Management, Inc.as of 31 Mar 2024 | 1.02m | 0.15% |
| Rafferty Asset Management LLCas of 31 Mar 2024 | 650.29k | 0.09% |
| Morgan Stanley & Co. LLCas of 31 Mar 2024 | 618.10k | 0.09% |
| Goldman Sachs & Co. LLC (Private Banking)as of 31 Mar 2024 | 608.10k | 0.09% |
More ▼
Data from 31 Mar 2024 - 31 Mar 2024Source: FactSet Research Systems Inc.
